BioVie Inc., a clinical-stage biotechnology company, is dedicated to the discovery, development, and commercialization of drug therapies in the United States. The company is headquartered in Santa Monica, California.
| Revenue (TTM) | 0 |
| Gross Profit (TTM) | 0 |
| EBITDA | $-22.47M |
| Operating Margin | 0.00% |
| Return on Equity | -150.80% |
| Return on Assets | -79.10% |
| Revenue/Share (TTM) | $0.00 |
| Book Value | $1.36 |
| Price-to-Book | 1.67 |
| Price-to-Sales (TTM) | — |
| EV/Revenue | - |
| EV/EBITDA | -11.66 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 0.00% |
| Shares Outstanding | $8.45M |
| Float | $7.48M |
| % Insiders | 0.60% |
| % Institutions | 25.16% |
Volatility is currently contracting
BioVie Inc (NASDAQ:BIVI, NASDAQ:BIVIW) announced that has completed the last on-treatment visit in its Phase 2 ADDRESS-LC clinical trial evaluating bezisterim in adults with Long COVID, with topline results targeted for release before the end of September 2026. The Carson City, Nevada-based clinical-stage company is developing therapies for neurological and neurodegenerative diseases.
CARSON CITY, Nev., Aug. 31, 2026 (GLOBE NEWSWIRE) -- BioVie Inc. (NASDAQ: BIVI) (“BioVie” or the “Company”), a clinical-stage company developing innovative drug therapies for neurological and neurodegenerative diseases, today announced that the last on-treatment visit of its ADDRESS-LC Phase 2 trial evaluating bezisterim for the treatment of neurological symptoms of Long COVID has been completed.
BioVie Inc. (BIVI) Discusses Bezisterim Mechanism of Action and SUNRISE-PD Phase II Trial Design Transcript
For years, the hunt for a Parkinson's disease-modifying drug came down to one protein: alpha-synuclein. Clear it out, the thinking went, and you slow the disease.
BioVie Inc (NASDAQ:BIVI, NASDAQ:BIVIW) said its drug candidate bezisterim met the prespecified endpoints of a Phase 2 trial in early-stage Parkinson's disease, with patients showing improvements in blood-based inflammatory markers and a range of clinical outcomes compared with placebo. The SUNRISE-PD trial was a multicenter, randomized, double-blind, placebo-controlled study in patients with early-stage Parkinson's disease who had not previously been treated with carbidopa/levodopa.
Patients treated with bezisterim demonstrated statistically significant improvements compared to placebo on both motor and non-motor symptoms, as assessed by MDS-UPDRS 1 Parts I, II, and III, as well as a composite endpoint comprising 15 clinically relevant measures. Bezisterim treatment appeared to have a beneficial impact on plasma biomarkers of neurodegeneration and reduced biomarkers of both neuro- and systemic-inflammation.
Shareholders are encouraged to contact the firm to discuss their rights and options at no cost or obligation. We would handle any matter on a contingent fee basis, whereby you would not be responsible for out-of-pocket payment of our legal fees or expenses.
BioVie Inc. (BIVI) Discusses Clinical Updates on Bezisterim and BIV201 for Parkinson's, Alzheimer's, and Ascites Transcript
BioVie Inc (NASDAQ:BIVI, NASDAQ:BIVIW) earlier this week announced that its Phase 2 long COVID trial evaluating bezisterim has achieved full enrollment, marking an important milestone for the biotechnology company as it advances a potential treatment for patients suffering persistent post-COVID symptoms. Speaking with Proactive, CEO Cuong Do said the study enrolled more than 200 long COVID patients with support from major medical institutions including Yale, Mount Sinai, Mayo Clinic and Stanford.
CARSON CITY, Nev., May 27, 2026 (GLOBE NEWSWIRE) -- BioVie Inc. (NASDAQ: BIVI) (“BioVie” or the “Company”), a clinical-stage company developing innovative drug therapies for neurological and neurodegenerative diseases, is pleased to invite investors to a webinar on June 2, 2026, at 4:15 p.m.
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on BIVI and any ticker you trade — then tracks every position and per-strategy win rate.
